Archive for 2011

Individual Biotechnology Management Cases now Available

I am pleased to announce the availability of  individual cases from Building the Case for Biotechnology Management Case Studies in Science, Laws, Regulations, Politics, and Business in digital and printed formats. The casebook, which was recently reviewed in Nature Biotechnology, features 22 case studies in science; law, regulation, politics; and business, and a foreword by […]


Drug Patent Expirations in June 2011

Drug Patent Expirations in June 2011 *Drugs may be covered by multiple patents  Tradename Applicant Generic Name Patent Number Patent Expiration FEMARA Novartis Pharms letrozole 4,978,672 Jun 3, 2011 TAZORAC Allergan tazarotene 5,089,509 Jun 13, 2011 AVAGE Allergan tazarotene 5,089,509 Jun 13, 2011 NUEDEXTA Avanir Pharms dextromethorphan hydrobromide; quinidine sulfate 5,166,207 Jun 17, 2011 […]


Neglected Disease Drug Development: Incentives for Success

This paper is a final project from the NIH Foundation for Advanced Education in the Sciences TECH 366, a course in Biotechnology Management Neglected Disease Drug Development: Incentives for Success Dr. Jason Chong How are treatments being developed for neglected diseases? Historically, pharmaceutical research and development (R&D) of drugs have been driven by the private […]


Maryland Incubator Company of the Year Finalists

It has been my pleasure to serve again on the selection committee for the Maryland Incubator Company of the Year. The finalists for the 2011 ICOY Awards come from all over the state and represent a diverse cross-section of technologies and services. In addition to the diverse categories, one incubator graduate company will be inducted […]


How many spam emails does it take to sell drugs on the Internet?

In short? A lot! As reported by the New York Times, it takes 12.5 million emails to earn $100 in Internet-based Viagra sales. The finding comes from a research group engaged in “spamalytics” — trying to find the mechanisms by which revenues are generated from spam. In their most recent paper they found that 95 […]


Going Global: Partnering and Investing in International Life Sciences

I will be presenting in an upcoming webinar: Going Global Partnering and Investing in International Life Sciences   Today, successful life sciences companies are feverishly evaluating international partnerships in search of places that are rapidly expanding. Some make the costly mistake of only using market size as the deciding factor, which is often misleading. Success […]


Therapies for Orphan Diseases: Public-Private Partnership in Drug Development

This paper is a final project from the NIH Foundation for Advanced Education in the Sciences TECH 366, a course in Biotechnology Management Therapies for Orphan Diseases: Public-Private Partnership in Drug Development Anuradha Ramamoorthy Research and development (R&D) of new drugs and therapies is both technologically and financially challenging.  As return on investment (ROI) in […]


Preview the next Scientific American Worldview

The next issue of Scientific American’s Worldview will be released at the BIO 2011 convention in late June. Worldview explores biotechnology development around the world, highlighting the opportunities and challenges in different markets. In the WorldView scorecard, I measure biotechnology innovation capacity around the world, and present multi-faceted data-driven comparisons to reveal greater clarity on […]